Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTRC | Q99895 | 3/20 | 0.38 |
| ▸ | ADORA3 | P0DMS8 | 4/20 | 0.36 |
| ▸ | CNR1 | P21554 | 1/20 | 0.35 |
| ▸ | GRM5 | P41594 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | CNR2 | P34972 | 1/20 | 0.33 |
| ▸ | PSD | A5PKW4 | 2/20 | 0.33 |
| ▸ | GSK3B | P49841 | 1/20 | 0.33 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.33 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19207325 | 0.91 | ALDH1A1 (0.38) | ADORA3MAPTGSK3BDYRK1AKDM4E | |
| SCHEMBL19207304 | 0.90 | CNR1 (0.45) | CTRCADORA3CNR1CNR2 | |
| SCHEMBL19259344 | 0.88 | SMN1; SMN2 (0.34) | CTRCMAPTKDM4EMEN1KMT2A | |
| SCHEMBL19259333 | 0.86 | CTRC (0.38) | CTRCADORA3CNR1GRM5MAPT | |
| SCHEMBL19207336 | 0.86 | CNR2 (0.41) | CTRCADORA3CNR1CNR2 | |
| SCHEMBL19642043 | 0.86 | GRM5 (0.35) | CNR1GRM5GSK3BDYRK1AKDM4E | |
| SCHEMBL19207260 | 0.85 | JAK2 (0.40) | CTRCADORA3CNR1CNR2GSK3B | |
| SCHEMBL19207311 | 0.84 | CTRC (0.37) | CTRCADORA3CNR1CNR2PSD | |
| SCHEMBL19207374 | 0.84 | CTRC (0.35) | CTRCADORA3CNR1MAPTCNR2 | |
| SCHEMBL19207276 | 0.82 | P2RY14 (0.44) | ADORA3KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108473462-B | Pyrazole-pyridine derivatives as EAAT3 inhibitors | 豪夫迈·罗氏有限公司 | 2021-06-22 | — | — | CN | claimed |
| EP-3411365-B1 | PYRAZOL-PYRIDINE DERIVATIVES AS EAAT3 INHIBITORS | HOFFMANN LA ROCHE (CH) | 2019-11-20 | — | — | EP | claimed |
| US-10457663-B2 | Pyrazol-pyridine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2019-10-29 | — | — | US | claimed |
| US-20180339975-A1 | PYRAZOL-PYRIDINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2018-11-29 | — | — | US | claimed |
| CN-108473462-B | Pyrazole-pyridine derivatives as EAAT3 inhibitors | 豪夫迈·罗氏有限公司 | 2021-06-22 | — | — | CN | disclosed |
| EP-3411365-B1 | PYRAZOL-PYRIDINE DERIVATIVES AS EAAT3 INHIBITORS | HOFFMANN LA ROCHE (CH) | 2019-11-20 | — | — | EP | disclosed |
| EP-3411365-B1 | PYRAZOL-PYRIDINE DERIVATIVES AS EAAT3 INHIBITORS | HOFFMANN LA ROCHE (CH) | 2019-11-20 | — | — | EP | disclosed |
| US-10457663-B2 | Pyrazol-pyridine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2019-10-29 | — | — | US | disclosed |
| US-10457663-B2 | Pyrazol-pyridine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2019-10-29 | — | — | US | disclosed |
| US-20180339975-A1 | PYRAZOL-PYRIDINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2018-11-29 | — | — | US | disclosed |
| WO-2017133990-A1 | PYRAZOL-PYRIDINE DERIVATIVES AS EAAT3 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2017-08-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10457663-B2 | Pyrazol-pyridine derivatives | MC3R, MC2R, DRD3 | CTRC 2889/4885ADORA3 136/4885CNR1 102/4885 |
| US-20180339975-A1 | PYRAZOL-PYRIDINE DERIVATIVES | MC3R, MC2R, DRD3 | CTRC 2889/4885ADORA3 136/4885CNR1 102/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.